GoodRx and Boehringer Ingelheim Announce Partnership

GoodRx and Boehringer Ingelheim Announce Partnership

Healthcare Tech Outlook | Wednesday, August 18, 2021

Doug Hirsch and Trevor Bezdek, Co-CEOs, Goodrx

Based on internal calculations, this integration and prospective integrations can save around 15 million dollars per year for patients who require life-enhancing drugs.

FREMONT, CA: GoodRx, America’s top healthcare savings resource, and Boehringer Ingelheim, a privately held, worldwide biopharmaceutical leader, recently announced a new partnership to expand patient access to GoodRx patient savings programs. Patients with type 2 diabetes or chronic obstructive pulmonary disease (COPD) can now easily enroll in manufacturer-sponsored copay programs for Boehringer Ingelheim’s leading array of pharmaceuticals to help lower their out-of-pocket costs, with more treatments potentially added in the future. Based on internal calculations, this integration and prospective integrations can save around 15 million dollars per year for patients who require life-enhancing drugs.

“As insurance deductibles increase, fewer medications are covered by insurance, and more restrictions are placed on the medications that are covered, patients are left carrying more of the economic burden,” said Bansi Nagji, President of Healthcare, GoodRx. “The integration of Boehringer Ingelheim’s savings programs will help lower the affordability barrier for patients so they can better access the medications they need.”

According to the CDC, diabetes affects one out of every ten Americans (more than 10 percent of the population), with 1.5 million new cases diagnosed each year. Access to diabetes drugs is an essential and frequently life-threatening aspect of continuous care, and cost is a significant barrier for many individuals with diabetes, with medical costs roughly 2.3 times those of people without diabetes. According to the CDC, COPD affects more than 16 million people and is the third-largest cause of death in the United States. The combined economic impact of both of these diseases is expected to be more than 286 billion dollars in direct medical costs each year (237 billion dollars for diabetes and 49 billion dollars for COPD).

Consumers seeking manufacturer savings programs for diabetes or COPD can visit the GoodRx website to see what Boehringer Ingelheim offers. Those who qualify with commercial insurance can find savings programs for their medication of Jardiance (empagliflozin)*, Synjardy (empagliflozin/metformin HCI)*, Synjardy XR (empagliflozin/metformin HCI extended-release)*, Spiriva Respimat (tiotropium bromide), Stiolto Respimat (tiotropium bromide and olodaterol) and Combivent Respimat (ipratropium bromide and albuterol). *products in the Boehringer Ingelheim and Eli Lilly and Company alliance portfolio.

“The combination of Boehringer Ingelheims commitment to the patients we serve and innovative approach to bringing transformative therapies to market, and GoodRxs trusted brand and reach, means that we will be able to provide more patients with seamless access to our support and savings programs,” said Chris Marsh, Senior Vice President, Market Access, Boehringer Ingelheim Pharmaceuticals. “We look forward to expanding our collaborative partnership with GoodRx so we can help more people living with chronic conditions find the appropriate savings program and lower their out-of-pocket costs.”

Weekly Brief